STAT+ reports Eli Lilly’s promotion of GLP-1 telehealth prescribing may face added conflict-of-interest complexity after Counsel Health announced it would be acquired by Oura. Counsel plans to integrate smart-ring data into clinician workflows to support diagnosis and treatment decisions. The concern is not about clinical performance per se, but the growing integration of GLP-1 prescribing networks with device-generated health data and the commercial relationships that pharma companies have with telehealth providers. Lilly previously listed Counsel clinicians as GLP-1 prescribers. If the acquisition proceeds, Lilly’s indirect visibility into Counsel’s data layer could widen questions around governance, transparency, and how patient data is handled across commercial and clinical stakeholders.